Who is sponsoring NCT02969447?

NCT02969447 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT02969447?

Interventions in NCT02969447: Administration of 10 units of intra venous oxytocin after fetal expulsion.

What condition does NCT02969447 study?

NCT02969447 studies Retained Placenta.

Is NCT02969447 still recruiting?

NCT02969447 is currently completed. Last updated 6 October 2017.

Last reviewed 2017-10-06 · How we verify

NCT02969447: ANDDROID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination

Completed Phase 4 Last updated 6 October 2017

What this trial tests

Phase 4 trial testing Administration of 10 units of intra venous oxytocin after fetal expulsion in Retained Placenta in 27 participants. Completed in 4 August 2017.

Timeline

20 October 2016

Primary endpoint
4 August 2017

4 August 2017

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	27
Start date	20 October 2016
Primary completion	4 August 2017
Estimated completion	4 August 2017
Sites	1 location across France

Drugs / interventions tested

Administration of 10 units of intra venous oxytocin after fetal expulsion — full drug profile →

Conditions studied

Retained Placenta — all drugs for Retained Placenta →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, female only, with Retained Placenta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective randomized trail which compare 2 regimens for third-stage management after second trimester medical pregnancy termination : 10UI intra venous oxytocin or no additional medication after fetal expulsion. Primary outcome was the incidence of placental retention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02969447 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 6 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02969447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing